Antibody Drug Conjugates for Cancer Therapy
Antibody Drug Conjugates for Cancer Therapy Antibody Drug Conjugates for Cancer Therapy
Naked antibodies are likely to be ineffective againsttargets selected simply on the basis of their expressionAntibody activatesor inhibits signalingNaked antibodiesAntibody recruitsimmune cellsArmed antibodiesAntibody specifiesdelivery of drugNKdrugInhibitionorDeathapoptosisdamagedruguptake
Bumps in the road from target identification to in vivo efficacyCopy #?Mean Tumor Volume1000800600400200vehiclecontrol ADC (6mg/kg)Targeted ADC (3mg/kg)prostate00 10 20 30Day40 50 60Single IVValidated mRNA profileEfficacious ADC
- Page 1 and 2: Antibody Drug Conjugates for Cancer
- Page 3: Target Screening- Large scale mRNA-
- Page 9 and 10: How many xenograft models should we
- Page 11 and 12: RelativeTenB2 expression in human p
- Page 13 and 14: Antibodies armed with auristatinsAN
- Page 15: MRP4 (multi drug resistance protein
- Page 18 and 19: Structure of the MUC16 antigen and
- Page 20 and 21: Endothelin B receptor: A target for
- Page 22 and 23: Melanocytes and EDNBR staining in n
- Page 24 and 25: Increased cell killing in vitro wit
- Page 26 and 27: ETBR Expression in Cell Lines versu
- Page 28 and 29: Efficacy/SafetyFour ways for armed
- Page 30 and 31: Antibody doses are normalized to dr
- Page 32 and 33: In Vivo Efficacy is Retained With T
- Page 34 and 35: Cumulative toxicity from long-lived
- Page 36: • GNE ADC Team- Susan Spencer- Ke
Bumps in the road from target identification to in vivo efficacyCopy #?Mean Tumor Volume1000800600400200vehiclecontrol ADC (6mg/kg)Targeted ADC (3mg/kg)prostate00 10 20 30Day40 50 60Single IVValidated mRNA profileEfficacious ADC
Change language